Kobashi Yoshihiro, Oka Mikio
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki-shi, Okayama 701-0192, Japan.
Kekkaku. 2008 Dec;83(12):779-84.
We performed a long-term retrospective investigation of pulmonary Mycobacterium avium complex (MAC) disease treated with combined chemotherapy following the ATS guideline or the Japanese Society for Tuberculosis guideline. We also studied when to terminate the combined chemotherapy.
The subjects of this study consisted of 90 patients who underwent combined chemotherapy according to these guidelines for minimum one-year period and followed up for at least one year since April, 1998.
The mean patients' age was 64.8 years old and the gender distribution consisted of 34 males and 56 females. While the sputum negative conversion was observed in 54 of 90 patients (60%), clinical improvement was recognized in 35 patients (39%) following combined chemotherapy administered according to the guidelines. Out of 54 patients with sputum conversion, 30 cases were followed up after the discontinuation of treatment, and sputum relapse later was seen in 18 patients. Out of 24 patients who continued the same treatment, sputum relapse was seen in 10 patients. Out of 35 patients with clinical improvement, 17 cases have been followed up after the discontinuation of treatment, clinical worsening was later recognized in 9 patients. Out of 18 patients who continued the same treatment, clinical worsening was recognized in 6 patients.
As the probability of sputum relapse after discontinuation of treatment was high even among patients whose sputum converted to negative by combined treatment according to the guidelines, we think that it is better to continue treatment according to the guidelines as long as possible.
我们按照美国胸科学会(ATS)指南或日本结核病协会指南,对采用联合化疗治疗的肺部鸟分枝杆菌复合群(MAC)病进行了长期回顾性研究。我们还研究了何时终止联合化疗。
本研究的对象包括90例患者,这些患者按照这些指南接受联合化疗至少一年,并自1998年4月起随访至少一年。
患者的平均年龄为64.8岁,性别分布为男性34例,女性56例。90例患者中有54例(60%)痰菌转阴,按照指南进行联合化疗后,35例患者(39%)有临床改善。在54例痰菌转阴的患者中,30例在治疗中断后进行了随访,18例患者后来出现痰菌复发。在继续相同治疗的24例患者中,10例出现痰菌复发。在35例有临床改善的患者中,17例在治疗中断后进行了随访,9例患者后来出现临床恶化。在继续相同治疗的18例患者中,6例出现临床恶化。
即使在按照指南联合治疗后痰菌转阴的患者中,治疗中断后痰菌复发的可能性也很高,因此我们认为最好尽可能长时间地按照指南继续治疗。